Circulating calprotectin as biomarker in neutrophil-related inflammation: Pre-analytical recommendations and reference values according to sample type

Clin Chim Acta. 2021 Jun:517:149-155. doi: 10.1016/j.cca.2021.02.022. Epub 2021 Mar 6.

Abstract

Background: Calprotectin (CLP) is a promising biomarker for the evaluation of neutrophil-related inflammation. Our aim was to establish reference values for circulating CLP in different sample types and to study the effect of pre-analytical variables.

Methods: Reference values were determined in 100 healthy individuals. Pre-analytical variables were evaluated in 10 healthy controls and four rheumatoid arthritis patients with active disease and covered sample type (serum with/without gel separator, heparin, EDTA and citrate plasma), pre-centrifugation time (<2 h, 6 h, 24 h), storage condition (2-8 °C, 18-25 °C, 30 °C) and storage time (24 h, 72 h, 7 days). CLP measurements were performed with the EliA™Calprotectin 2 assay on Phadia™200 (Thermo Fisher Scientific).

Results: In healthy controls, baseline CLP concentrations in serum were more than double the concentration in EDTA and citrate plasma (0.909 µg/mL versus 0.259 µg/mL and 0.261 µg/mL respectively). Heparin, EDTA and citrate stabilized CLP concentrations for up to 6 h before centrifugation, whereas significant increases in CLP levels were observed when serum was left untreated during that time period.

Conclusion: Clinical studies on circulating CLP need to apply sample type-specific reference values and decision limits. To obtain reproducible CLP results in serum, more stringent pre-analytical sample handling instructions are needed.

Keywords: Biomarker; Circulating calprotectin; Neutrophil-related inflammation; Pre-analytical phase; Reference values.

MeSH terms

  • Biomarkers
  • Blood Specimen Collection
  • Humans
  • Inflammation / diagnosis
  • Leukocyte L1 Antigen Complex*
  • Neutrophils*
  • Reference Values

Substances

  • Biomarkers
  • Leukocyte L1 Antigen Complex